Potassium-sparing diuretics

Slides:



Advertisements
Similar presentations
Chapter 51 Diuretic Agents
Advertisements

Diuretics Clinical Conditions Requiring Diuretic Therapy:
THIAZIDE DIURETICS Secreted into the tubular lumen by the organic acid transport mechanisms in the proximal tubule Act on the distal tubule to inhibit.
Diuretics. A. Kidney functions Kidneys have a number of essential functions:
Chapter 41 Diuretics 1.
Diuretics and Dehydrants. §1 Diuretics Abnormalities in fluid volume and electrolyte composition are common and important clinical problems. Drugs that.
1 Lecture-5 Dr. Zahoor. Objectives – Tubular Secretion Define tubular secretion Role of tubular secretion in maintaining K + conc. Mechanisms of tubular.
DIURETICS. Functions of the kidneys Volume Acid-base balance Osmotic pressure Electrolyte concentration Excretion of metabolites and toxic substances.
Mineralocorticoid Excess Hyperaldostronism. Epidemiology first description of a patient with an aldosterone-producing adrenal adenoma (Conn's syndrome)
Diuretics A diuretic is a substance that increases the rate of urine volume output Most diuretics also increase urinary excretion of solutes, especially.
Diuretics. Why do we want to know about diuretics? What do kidneys do? What can go wrong? Interventions that can be used how do they work? Effects, side.
Excretion of Water and Electrolytes
DIURETICS Brogan Spencer and Laura Smitherman. What is a diuretic? Substance that promotes the formation (excretion) of urine.
Control of Renal Function. Learning Objectives Know the effects of aldosterone, angiotensin II and antidiuretic hormone on kidney function. Understand.
Antihypertensives Chad Byworth. Hypertension What is hypertension? Blood pressure of greater than 140 systolic or 90 diastolic, confirmed in primary care.
Role of Kidneys In Regulation Of Potassium Levels In ECF
Diuretics Chris Hague, PhD
DIURETICS By: Prof. A. Alhaider.
Diuretics iii Aldosterone antagonist & Sodium Channel Inhibitors.
Diuretics. From Knauf & Mutschler Klin. Wochenschr : % 20% 5% 4.5% 0.5% Volume 1.5 L/day Urine Na 100 mEq/L Na Excretion 155 mEq/day.
Diuretic Agents in Hypertension and other disorders
Drugs Acting on the Renin-Angiotensin-Aldosterone System
Prof. Hanan Hagar Pharmacology Department
DIURETICS: (know those used to Tx hypertension and HF) Thiazide diuretics: hydrochlorothiazide Loop diuretics: furosemide, ethacrynic acid Potassium-sparing.
Diuretics Remove sodium & water
DIURETIC DRUGS.
1-Overview 2-Classification 3-Indiviual drugs 1-Indications of Diuretics. 2-Adverse effects. 3-Mannitol and Carbonic Anhydrase inhibitors.
Diuretics the role of different portions of the nephron in ion exchange; the sites of action and pharmacology of diuretics; the therapeutic applications.
CARBONIC ANHYDRASE INHIBITORS ACETAZOLAMIDE E It is a sulfonamide derivative. It is a sulfonamide derivative. noncompetitively but reversible inhibits.
DIURETICS Part 1 Prof. Hanan Hagar Pharmacology Unit.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 25 Diuretics.
DIURETIC DRUGS (DR.Farooq Alam) DIURETIC DRUGS (DR.Farooq Alam)
DIURETICS Part 1 Prof. Hanan Hagar Pharmacology Department.
Prof. Hanan Hagar Pharmacology Department
Armed Forces Academy of Medical Sciences
CHRONIC CONGESTIVE HEART FAILURE American Heart Association in collaboration with Sociedad Española de Cardiologia June, 1999 CHRONIC CONGESTIVE HEART.
DIURETICS Diuretics are drugs which increase the excretion of sodium and water from the body by an action on the kidney. Their primary effect is to decrease.
DR. MOHD NAZAM ANSARI.  Some of pathological conditions associated with retention of sodium and water in the body e.g. Congestive Heart failure, Pulmonary.
Drugs Used for Diuresis Chapter 29 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Diuretic Agents.
Class 4- LOOP DIURETICS High ceiling Diuretics
DIURETICS How do they work? WHAT DO THEY DO? When do I use them? How do I use them?
Pharmacology – I [PHL 313] DiureticsDiuretics Dr. Hassan Madkhali Assistant Professor Department of Pharmacology E mail:
Mosby items and derived items © 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 21 Diuretic Agents.
DIURETICS By: Prof. A. Alhaider 1433 H. Anatomy and Physiology of Renal system ► Remember the nephron is the most important part of the kidney which regulates.
DIURETICS By: Prof. A. Alhaider. Anatomy and Physiology of Renal system ► Remember the nephron is the most important part of the kidney that regulates.
What is high ceiling diuretic & Why?
MCQs from High yield areas of Diuretic Pharmacology
Diuretic Agents. Carbonic Anhydrase Inhibitors.
POTASSIUM-SPARING DIURETICS 1.Aldosterone antagonists: Spironolactone and eplerenone: The spironolactone-receptor complex is inactive complex results in.
Diuretics Blake Briggs, Class of 2017.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Objectives for Lecture on Diuretics
Diuretics.
Drugs Used for Diuresis
Drugs Effecting Body Fluids and Volume
Sodium Channel Inhibitors
(Furosemide, Ethacrynic acid, Bumetanide and Torsemide) DIURETICS: LOOP DIURETICS (Furosemide, Ethacrynic acid, Bumetanide and Torsemide)
Medication and Acute Kidney Injury
Renal tubule transport mechanisms
Loop diuretics Domina Petric, MD.
D. C. Mikulecky Faculty Mentoring Program Virginia Commonwealth Univ.
Carbonic anhydrase inhibitors
Clinical pharmacology of diuretic agents
Domina Petric, MD Aquaretics.
Thiazides Domina Petric, MD.
Drugs Acting on the Renin-Angiotensin-Aldosterone System
Pathophysiology of Renal Tubular Acidosis: Core Curriculum 2016
Diuretics By S.Bohlooli, PhD.
Diuretic Drugs.
Presentation transcript:

Potassium-sparing diuretics Domina Petric, MD

Introduction Potassium-sparing diuretics prevent potassium secretion by antagonizing the effects of aldosterone in collecting tubules. Inhibition may occur by: direct pharmacologic antagonism of mineralocorticoid receptors (spironolactone, eplerenone) inhibition of sodium influx through ion channels in the luminal membrane (amiloride, triamterene)

Pharmacokinetics Spironolactone is a synthetic steroid that acts as competitive antagonist to aldosterone. Substantial inactivation of spironolactone occurs in the liver. It has slow onset of action, requiring several days before full therapeutic effect is achieved.

Pharmacokinetics Eplerenone is a spironolactone analog with much greater selectivity for the mineralocorticoid receptor. It is several hundredfold less active on androgen and progesterone receptors than spironolactone: fewer adverse effects.

Pharmacokinetics Amiloride and triamterene are direct inhibitors of sodium influx in the cortical collecting tubule (CCT). Triamterene is metabolized in the liver. Renal excretion is a major route of elimination for the active form of triamterene and the metabolites.

Pharmacokinetics Triamterene is extensively metabolized and it has shorter half-life. It must be given more frequently than amiloride, which is not metabolized.

Pharmacodynamics Potassium-sparing diuretics reduce sodium absorption in the collecting tubules and ducts. Potassium absorption and secretion at this site is regulated by aldosterone. Aldosterone antagonists interfere with this process.

Pharmacodynamics Spironolactone and eplerenone bind to mineralocorticoid receptors and blunt aldosterone activity. Amiloride and triamterene do not block aldosterone. They directly interfere with sodium entry through the epithelial Na+ channels (ENaC) in the apical membrane of the collecting tubule.

Pharmacodynamics Potassium secretion is coupled with sodium entry in the collecting tubule: potassium-sparing effect.

Pharmacodynamics The actions of the aldosterone antagonists depend on renal prostaglandin production. The actions of potassium-sparing diuretics can be inhibited by NSAIDs.

Dosage, combinations Trade Name Potassium-sparing agent Hydrochlorothiazide Aldactazide Spironolactone 25 mg 50 mg Aldactone Spironolactone 25, 50 or 100 mg Dyazide Triamterene 37,5 mg 25 mg Dyrenium Triamterene 50 or 100 mg Inspra Eplerenone 25, 50 or 100 mg Maxzide Triamterene 75 mg Maxzide-25 mg Midamor Amiloride 5 mg Moduretic

Clinical indications States of mineralocorticoid excess or hyperaldosteronism (aldosteronism): PRIMARY hypersecretion: Conn´s syndrome, ectopic adrenocorticotropic hormone production SECONDARY hyperaldosteronism: evoked by heart failure, hepatic cirrhosis, nephrotic syndrome

Clinical indications Thiazides and loop agents can cause or exacerbate volume contraction and may cause secondary hyperaldosteronism. These agents also cause potassium wasting. Potassium-sparing diuretics blunt the potassium secretory response.

Clinical indications Eplerenone 25-50 mg/day may interfere with some of the fibrotic and inflammatory effects of aldosterone. It can slow progression of albuminuria in diabetic patients. Eplerenone can reduce myocardial perfusion defects after myocardial infarction.

Clinical indications Eplerenone can also reduce mortality rates in patients with mild to moderate heart failure after myocardial infarction.

Toxicity Hyperkalemia Hyperchloremic metabolic acidosis Gynecomastia Acute renal failure Kidney stones

Hyperkalemia These agents reduce urinary excretion of potassium. They can cause mild, moderate or even life-threatening hyperkalemia.

Hyperkalemia The risk is increased by: renal disease use of other drugs that reduce or inhibit renine (β blockers, NSAIDs, aliskiren) use of drugs that reduce angiotensin II activity (ACE-inhibtors, angiotensin receptor inhibitors).

Hyperkalemia With fixed-dosage combinations of potassium-sparing and thiazide diuretics, the thiazide-induced hypokalemia and metabolic alkalosis are ameliorated. It is preferable to adjust the doses of the two drugs separately because thiazide-associated adverse effects predominate in fixed combinations.

Hyperchloremic metabolic acidosis Potassium sparing diuretics cause acidosis similar to acidosis in type IV renal tubular acidosis by inhibiting hydrogen ions secretion in parallel with potassium secretion.

Gynecomastia Spironolactone can cause gynecomastia, impotence and benign prostatic hyperplasia.

Acute renal failure Triamterene and indomethacin combination has been reported to cause acute renal failure.

Kindey stones Triamterene is only slightly soluble. It may precipitate in the urine, causing kidney stones formation.

Contraindications Potassium-sparing agents can cause severe, even fatal, hyperkalemia in susceptible patients. Patients with chronic renal insufficiency are especially vulnerable.

Contraindications Patients with liver disease may have impaired metabolism of triamterene and spironolactone. Strong CYP3A4 inhibitors can increase blood levels of eplerenone: erythromycin, fluconazole, diltiazem, grapefruit juice.

Loop agents and thiazides combinations

Loop agents and thiazides Some patients are refractory to the usual dose of loop diuretics or become refractory after an inital response. These agents have a short half-life (2-6 hours). Refractoriness may be due to an excessive interval between doses.

Loop agents and thiazides Renal sodium retention may be greatly increased during the time period when the drug is no longer active. After the dosing interval for loop agents is minimized or the dose is maximized, the use of two drugs acting at different nephron sites may exhibit synergy.

Loop agents and thiazides Salt reabsorption in either the thick ascending limb (TAL) or the distal convoluted tubule (DCT) can increase when the other segment is blocked. Inhibition of both can produce additive diuretic response.

Loop agents and thiazides Thiazide diuretics often produce a mild natriuresis in the proximal tubule that is usually masked by increased reabsorption in the TAL. The combination blocks sodium reabsorption from all three segments. Combination can mobilize large amounts of fluid.

Loop agents and thiazides Close hemodynamic monitoring of the patients on combination is necessary, as well as careful monitoring of fluid and electrolyte status, especially potassium.

Literature Katzung, Masters, Trevor. Basic and clinical pharmacology.